Summary Lonidamine (LND) is a new anti-cancer drug which interferes with the energy-yielding processes of tumour cells without affecting DNA replication. A total of 69 previously untreated patients with non-small cell lung cancer (NSCLC) entered this study. LND was given orally as a single agent at doses ranging from 450 to 900 mg day-' until tumour progression (2 to > 1,402 days). Partial responses (PR) occurred in 7/69 patients (10.1%); 4/25, 1/27 and 2/9 for epidermoid, adenocarcinoma and large cell cancer respectively. PR by stage was 4/10, 1/3, 1/20 and 1/28 for stages I, II, III and IV, respectively. The median duration of response was 303 days (,>61 to > 338 days). The median survival for the whole group was 261 days. Toxicity was assessed in all patients. No myelosuppression occurred. The main side-effects were myalgia (68%), loss of appetite (23%), asthenia (20%) and testicular pain (13%). Doses above 450 mg day-' produced more severe side-effects without any improvement in therapeutic activity.
Lonidamine (LND; 1 (2,4)-chlorobenzyl-1 H-indazole-3-carboxylic acid) has been shown to exert anti-spermatogenic (Coulston et al., 1975) , anti-tumour (Silvestrini et al., 1983) and embryotoxic (Scorza et al., 1982) activities in laboratory animals. It inhibits the energy processes characteristic of some tissues, such as the seminiferous epithelium and tumour cells (De Martino et al., 1979) . At active doses against spermatogenesis it is practically devoid of toxic effects and other marked pharmacological actions (Cioli et al., 1984) . In phase I studies the drug was adequately tolerated; myalgia was the dose-limiting toxic effect (Band et al., 1984) . This phase II study was performed in order to ascertain the anti-tumour activity of LND in patients with non-small cell lung cancer (NSCLC). The report describes the completed study in detail; brief preliminary descriptions have appeared earlier (Kokron et al., 1984) .
Materials and methods
From November 1981 to December 1983, 70 consecutive patients with non-small cell lung cancer were admitted to the study and followed up to December 1986. Conditions for admission to the study were: informed consent, no previous chemotherapy, inoperable stage (Miller et al., 1983) . No change (NC), less than 25% decrease in total tumour size or less than 25% increase in the size of one or more measurbale lesions. Progressive disease (PD), a 25% or more increase in the size of one or more lesions, or the appearance of new lesions.
Patients were considered evaluable for response after a minimum of 4 weeks of therapy and evaluable for toxicity from initiation of treatment.
Survival was measured from the start of treatment accord- Sixty-nine patients were evaluable for tolerance and 61 for response. Three patients refused the treatment because of side-effects after 2 days (general indisposition), 3 days (nausea and myalgia) and 9 days (headache and myalgia), respectively.
Treatment was discontinued due to severe muscular pain after 10 and 15 days in two patients, worsening of general condition after 10 days in one patient and cholestatic jaundice after 19 days in one patient. This last patient had a daily dose of 900 mg LND; cholestasis normalised after discontinuation of treatment and another 3 weeks. This patient's survival from the beginning of LND was 157 days. One further patient did not return for the first check-up and was lost to follow-up. The remaining 61 patients were treated with LND until tumour progression occurred (29 Table III. Myalgia, gastrointestinal disturbances, loss of appetite, asthenia and testicular pain, diminished hearing and jointpain were the most frequent symptoms due to LND. Myalgias generally occurred within the first 2 days of treatment and most of the other side-effects within a fortnight. In the majority of cases they either remained at a tolerable level or disappeared spontaneously after a few days, despite continued treatment. Grade 4 melena was observed in a patient with a history of peptic ulcer. Although the frequency of myalgia, asthenia and testicular pain was similar at the two dose levels tested, they were more severe at the higher level.
Increase of serum alkaline phosphatase was observed in four cases (grade 1) and one case (grade 2) respectively. There was increased serum bilirubin in one patient (grade 3), BUN in three (grade 1), serum creatinine in one (grade 1), serum LDH in one (grade 1) and uric acid in one (grade 1), and in six patients with epidermoid cancer and progressive disease hypercalcaemia occurred (four of them also had temporary elevated serum calcium before LND treatment).
Discussion
Lonidamine, used a single agent, was shown to have an activity against inoperable NSCLC in 11% of the evaluable patients. Stages I and II responded better than stages III and IV. Better results were obtained in epidermoid carcinomas (PR = 16%). Daily doses above 450 mg induced more severe side-effects without improvement in therapeutic activity.
As far as tolerance was concerned, despite the frequent occurence of myalgias we never observed a grade 4 toxicity even at high doses, and this side-effect, like all the others, promptly disappeared with the suspension of treatment.
There was no evidence of myelosuppression. As far as changes in renal and liver function tests were concerned, although they are difficult to attribute to LND (we also observed a normalisation of these parameters in patients with abnormal basal values), their close monitoring is suggested.
LND combined with standard cytotoxic chemotherapy may be expected to have favourable combination effects because of the completely different mechanism of action and different spectrum of toxicity. On the basis of the results obtained in this study we have now started a randomised trial on the combination of LND with chemotherapy in NSCLC.
